These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38519031)

  • 1. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression.
    Lee YH; Yoon AR; Yun CO; Chung KC
    J Biol Chem; 2024 Apr; 300(4):107206. PubMed ID: 38519031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK3 phosphorylates SNAPIN to regulate axonal retrograde transport and neurotransmitter release.
    Lee YH; Suh BK; Lee U; Ryu SH; Shin SR; Chang S; Park SK; Chung KC
    Cell Death Discov; 2022 Dec; 8(1):503. PubMed ID: 36585413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
    Kim K; Lee S; Kang H; Shin E; Kim HY; Youn H; Youn B
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.
    Guo X; Williams JG; Schug TT; Li X
    J Biol Chem; 2010 Apr; 285(17):13223-32. PubMed ID: 20167603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
    Wippich F; Bodenmiller B; Trajkovska MG; Wanka S; Aebersold R; Pelkmans L
    Cell; 2013 Feb; 152(4):791-805. PubMed ID: 23415227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
    Ma F; Zhu Y; Liu X; Zhou Q; Hong X; Qu C; Feng X; Zhang Y; Ding Q; Zhao J; Hou J; Zhong M; Zhuo H; Zhong L; Ye Z; Xie W; Liu Y; Xiong Y; Chen H; Piao D; Sun B; Gao Z; Li Q; Zhang Z; Qiu X; Zhang Z
    Hepatology; 2019 Nov; 70(5):1785-1803. PubMed ID: 31066068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAICS/DYRK3 Multienzyme Interactions as Coregulators of Purinosome Formation and Metabolism on Radioresistance in Oral Squamous Cell Carcinoma.
    Huang CS; Hsieh MS; Yadav VK; Wu YC; Liu SC; Yeh CT; Huang MS
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90-mediated regulation of DYRK3 couples stress granule disassembly and growth via mTORC1 signaling.
    Mediani L; Antoniani F; Galli V; Vinet J; Carrà AD; Bigi I; Tripathy V; Tiago T; Cimino M; Leo G; Amen T; Kaganovich D; Cereda C; Pansarasa O; Mandrioli J; Tripathi P; Troost D; Aronica E; Buchner J; Goswami A; Sterneckert J; Alberti S; Carra S
    EMBO Rep; 2021 May; 22(5):e51740. PubMed ID: 33738926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival.
    Li K; Zhao S; Karur V; Wojchowski DM
    J Biol Chem; 2002 Dec; 277(49):47052-60. PubMed ID: 12356771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal cell kinase (ICK) promotes activation of mTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908.
    Wu D; Chapman JR; Wang L; Harris TE; Shabanowitz J; Hunt DF; Fu Z
    J Biol Chem; 2012 Apr; 287(15):12510-9. PubMed ID: 22356909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR-mediated Na
    Yang Y; Luo Z; Hao Y; Ba W; Wang R; Wang W; Ding X; Li C
    Biomed Pharmacother; 2017 Aug; 92():744-749. PubMed ID: 28591687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
    Huang S; Yang ZJ; Yu C; Sinicrope FA
    J Biol Chem; 2011 Nov; 286(46):40002-12. PubMed ID: 21949121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
    Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway.
    Yang Y; Ma S; Ye Z; Zhou X
    J Cell Biochem; 2020 Feb; 121(2):1283-1294. PubMed ID: 31535400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells.
    Ondrušová L; Réda J; Záková P; Tuháčková Z
    Folia Biol (Praha); 2013; 59(4):162-7. PubMed ID: 24093774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyrk kinases regulate phosphorylation of doublecortin, cytoskeletal organization, and neuronal morphology.
    Slepak TI; Salay LD; Lemmon VP; Bixby JL
    Cytoskeleton (Hoboken); 2012 Jul; 69(7):514-27. PubMed ID: 22359282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM; Alessi DR
    Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
    Melick CH; Jewell JL
    Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.
    Harwood FC; Shu L; Houghton PJ
    J Biol Chem; 2008 Feb; 283(5):2575-85. PubMed ID: 18056704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
    Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
    Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.